DAY THREE - Plenary Session - Wednesday 23rd May 2012

last modified: 22 May '12

Please enable javascript to see more information on speakers

1.50pm

Chairman’s opening remarks

Prof. Chris Mason

Prof. Chris Mason MBBS, PhD, FSB, FRCSI, FRCS Stem Cell & Regenerative Medicine Bioprocessing Unit Advanced Centre for Biochemical Engineering University College London Mason is internationally recognized to be at the forefront of the emerging...

more..

› Prof. Chris Mason, Chair of Regenerative Medicine Bioprocessing, UCL

ACCESS TO FUNDING AND ESTABLISHING COLLABORATIONS

1.55pm

Understanding what the general trends of investment in this industry

Edward Tenthoff

Ted Tenthoff is a managing director and senior research analyst at Piper Jaffray, focused on the drug discovery sector of the biotech industry. Prior to joining Piper Jaffray in 2003, Tenthoff worked at Think Equity Partners. Prior to that, he...

more..

What are the different models available for generating capital?
What is getting investors excited?
How can promising therapies establish the relationships and funding they need?
How is funding best delivered to basic or translational research?

› Edward Tenthoff, Managing Director, Senior Research Analyst, Piper Jaffray & Co.

2.20pm

Panel discussion: committing to maintain investment to continue the momentum

George Emont

George Emont is a Managing Partner with Triathlon Medical Ventures and also a Managing Partner of the Kentucky Seed Capital Fund. Mr. Emont's 25 years of health care industry experience include 15 years in venture capital. Prior to joining Triathlon ...

more..

Greg Bonfiglio

Mr. Bonfiglio is the Founder & Managing Partner of Proteus, LLC – an investment and advisory firm focused solely on regenerative medicine. Proteus provides fund management, consulting, and investment banking services to the regenerative medicine...

more..

Cathy Prescott

Cathy brings over 20 years of experience in research, management and business within the life-science and venture capital sectors. She is the Founder Director of Biolatris Ltd., Co-founder and Director of Univercell Market Ltd., Chair of the UK...

more..

Shosh Merchav

Dr. Shosh Merchav has been involved in the field of Regenerative Medicine since the early 80's, both in the Academic as well as Industrial setting. Dr Merchav joined Teva in 2006 and has headed the Cell Therapy Projects Unit at Teva Innovative...

more..

What is attracting investors to innovative cutting edge research?
Partnering to drive forward therapeutics an drug discovery
How are investors establishing a sustainable portfolio of stem cell therapy products?
Innovative funding models and establishing the collaborations to start up successfully for a cell therapy

2.55pm

Best practice to advance the stem cell pipeline through mutually beneficial partnerships

Ram Mandalam

Ramkumar Mandalam, Ph.D. is President and CEO of Cellerant Therapeutics Inc, a clinical stage biotechnology company developing novel therapies for cancer treatment and blood-related disorders. Prior to joining Cellerant as VP of Pharmaceutical...

more..

Advancing through to phase 1/2
What are the viable options for stem cell therapy innovators to gain access to funds and progress to clinic and beyond?
What is best practice to seek, establish and follow through with fruitful collaborations?
What is the future for Cellerant’s off the shelf stem cell-based medicine?

› Ram Mandalam, CEO, Cellerant Therpaeutics

DETERMINING THE VALUE OF FUTURE CELL THERAPIES

3.20pm

Concept of value and recommendations for cell therapies – NICE perspective

Fay McCracken

Fay McCracken joined the NICE Technology Appraisal Programme at NICE in 2008, having previously worked in the pharmaceutical industry and in strategic market access and health economic consulting. Since 2011 she has provided technical leadership for ...

more..

› Fay McCracken, Medical Technologies Evaluation Programme Technical Advisor, NICE

3.45pm

Concept of value and recommendations for cell therapies – CMS perspective

Louis Jacques

Dr Jacques joined CMS in 2003 and has been director of the Coverage and Analysis Group (CAG) since October 2009. The group reviews evidence and develops Medicare national coverage policy. From 2004 through 2009 he was Director of the Division of...

more..